Myology research highlights

RSS feed

New roles for CaVβs subunits in the regulation of gene expression and cellular homeostasis

. Voltage-gated calcium channels (CaVs or VGCCs) regulate intracellular calcium homeostasis. . Their activation by electrical activity leads to changes in intracellular Ca2+ levels regulating, depending on the cell type, various processes such as contraction, secretion and gene expression. . While the CaVα1 subunit is the essential component of the calcium channel, the auxiliary β, … [Read more]

Launch of the 1st European gene therapy clinical trial in LGMD linked to FKRP

The first European gene therapy trial in limb-girdle muscular dystrophy linked to the FKRP gene (LGMD2I/R9) has just started. This is a multicentre phase 1-2 study evaluating the safety, pharmacodynamics, efficacy and immunogenicity of GNT0006, an adeno-associated virus (AAV) vector carrying the human FKRP transgene. This study will consist of two phases: an open-label dose … [Read more]

Andersen-Tawil syndrome: phenotypical variability and atypical presentations in a French cohort

Andersen-Tawil syndrome (ATS) is a rare muscle channelopathy linked to mutations in the KCNJ2 gene. This syndrome combines to varying degrees the clinical triad of periodic paralysis, cardiac arrhythmias and dysmorphic syndrome. The muscle phenotype is still being characterised. A French study, involving clinicians from the Institute, was carried out on 35 patients with ATS … [Read more]

Effects of Prox1 overexpression in mdx dystrophic muscle

In Duchenne muscular dystrophy, increased muscle fragility appears to be the cause of muscle stem cell depletion, which leads to muscle wasting and thus muscle weakness. Chronic voluntary exercise can reduce some of the susceptibility to contraction-induced muscle damage, that is muscle fragility.  In this paper, a French team involving researchers from the institute studied the … [Read more]

International guidelines for the management of CMT in children

Guidelines for the management of children with Charcot-Marie-Tooth disease have been published. No drug treatment has been proven to be effective (including high dose vitamin C or botulinum toxin). Orthopaedic treatment combines active physiotherapy, stretching of joints that tend to stiffen and painful muscles, orthopaedic devices (night brace, foot lift splint, etc.), sensitivity rehabilitation and … [Read more]

The time to diagnosis of DMD has not shortened in the US in the last 20 years

It still takes 2.2 years from the first signs of the disease to the confirmation of the genetic diagnosis of Duchenne muscular dystrophy (DMD). This is the finding of a study by the MD STARnet. Analysis of the records of 221 boys with Duchenne muscular dystrophy with no family history and born between 1 January … [Read more]

Late-onset MADD: a polymorphic clinical picture that responds to riboflavin

An Italian team reports data from a series of 10 patients (seven men) with late-onset multiple acyl-CoA dehydrogenase deficiency (MADD), with no family history. Symptoms were very varied and began between the ages of 12 and 62 years, often abruptly or evolving rapidly: myalgia and discomfort when walking, fatigue, exercise intolerance, muscle weakness, difficulty in … [Read more]

Gene therapy extinction of the dominant centronuclear myopathy mutation is still effective one year later in mice

The proof of concept of an early treatment with an siRNA specifically silencing the mutated allele of the DNM2 gene in a mouse model and in human fibroblast-derived cells carrying the most frequent mutation in centronuclear myopathy (p.R465W) was published in 2018 by a team from the Research Centre of the Institute of Myology (Paris) … [Read more]

RYR1-related congenital multi-minicore myopathy: proof of concept in mice for a pharmacological treatment targeting epigenetic changes

A Swiss team has created a mouse model of RYR1-related congenital multi-minicore myopathy with a heterozygous mutation of RYR1 that is isogenic to the one that causes a severe form of congenital multi-minicore myopathy in humans. Treatment of these mice, which have many features of the human disease, with two molecules targeting DNA methylases (decitabine) … [Read more]

Triheptanoin does not improve physical performance in people with Tarui disease

In a double-blind, placebo-controlled crossover trial, a Danish team evaluated the effects of 14 days of tripheptanoin in three people with phosphofructokinase deficiency (PFKD) or type VII glycogenosis (Tarui disease) on exercise heart rate and fatty acid oxidation. The idea was to short-circuit the deficit in energy production by the Krebs cycle resulting from the … [Read more]